Printer Friendly

Syntagon to Supply Clinical Material for Parkinson's, Huntington's Research.

STOCKHOLM, Sweden -- Specialist contract research organisation, Syntagon AB, is to develop the lead compound for Phase I clinical trials carried out by A. Carlsson Research AB into Parkinson's disease, Huntington's disease and Brain Fatigue.

"We are immensely proud to be a part of this new phase of research into these debilitating conditions," says John Cameron, Syntagon Director of Sales & Marketing Europe.

In the first set of clinical trials, A. Carlsson Research will explore the effect of OSU 6162 on Parkinson's, Huntington's and Brain Fatigue.

Arvid Carlsson, CEO of Arvid Carlsson Research, won the Nobel Prize in Physiology or Medicine in 2000 for his discovery of dopamine's function as a neurotransmitter. His research resulted in the discovery that Parkinson's is caused by a lack of dopamine in certain parts of the brain.

"We had heard good reports about Syntagon within the Swedish community. They are technically excellent, fast-responding and an ideal partner for a company of our size," Carlsson says.

With twin operations in Sodertalje, Sweden, and Riga, Latvia, Syntagon specialises in synthetic preparation of small molecules under GMP manufacture.

Syntagon's extensive pharmaceutical experience, expertise in GMP manufacture, analytical chemistry and crystallisation are tailored for all client types: from single-product start-ups, to global pharmaceutical groups.

Syntagon is a leading Scandinavia-based drug development partner. We develop compounds from lead optimisation to phase II clinical trials using the latest technology and equipment combined with a solid quality system.

This information was brought to you by Cision http://www.cisionwire.com

COPYRIGHT 2009 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2009 Gale, Cengage Learning. All rights reserved.

 
Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Apr 15, 2009
Words:247
Previous Article:Research and Markets: Singapore Insurance Report Q1 2009 - Available Now.
Next Article:Research and Markets: Financial Deals Industry Tracker - Retail, Annual Round-up 2008 - Available Now.
Topics:


Related Articles
Pig cells used for Parkinson's disease.
Antibiotic now tackles Parkinson's. (Biomedicine).
Clinical trial update.
Mutation linked to some cases of Parkinson's: identifying gene raises ethical questions about its use in testing, given the lack of preventive...
New developments in skin firmness and elasticity.
Neural transplantation for the treatment of Parkinson's disease.
Avicena files composition of matter patent application for treatment of Parkinson's Disease.

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters